To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment-Reference-Cited by-同舟云学术

To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment

Published:2021-03-11 Issue:8 Volume:35 Page:1201-1208
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Mounzer Karam,Brunet Laurence,Wyatt Christina M.,Fusco Jennifer S.,Vannappagari Vani,Tenorio Allan R.,Shaefer Mark S.,Ragone Leigh,Hsu Ricky K.,Fusco Gregory P.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference16 articles.

1. The separated enantiomers of 2’-deoxy-3’-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro;Coates;Antimicrob Agents Chemother,1992

2. Activities of the four optical isomers of 2’,3’-dideoxy-3’-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes;Schinazi;Antimicrob Agents Chemother,1992

3. Antihuman immunodeficiency virus type 1 activity and in vitro toxicity of 2’-deoxy-3’-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog;Soudeyns;Antimicrob Agents Chemother,1991

4. A phase I/II study of 2’-deoxy-3’-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection;Pluda;J Infect Dis,1995

5. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study;van Leeuwen;J Infect Dis,1995

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling;Pharmaceutics;2023-05-06

2. Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction;The Brazilian Journal of Infectious Diseases;2023-05

3. Short‐term toxicity assessment of combined use of zidovudine, lamivudine and lopinavir/ritonavir in vitro and in vivo;Basic & Clinical Pharmacology & Toxicology;2023-04-27

4. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12

5. Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function;Expert Review of Clinical Pharmacology;2022-05-04